NasdaqGM:CRSPBiotechs
A Look At CRISPR Therapeutics (CRSP) Valuation As CASGEVY Progress And New Funding Lift Investor Interest
CRISPR Therapeutics (CRSP) is back in focus after first quarter 2026 results showed revenue of US$1.46 million and a net loss of US$122.93 million, along with ongoing commentary about CASGEVY commercialization.
See our latest analysis for CRISPR Therapeutics.
The latest earnings update, CASGEVY launch commentary and the US$600 million convertible notes issue come against a backdrop of a 12.29% 90 day share price return, a 45.86% one year total shareholder return and weaker three and five year...